CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
CVRx (CVRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx Q1 Earnings Call Highlights
CVRx NASDAQ: CVRX reported first-quarter 2026 revenue of $14.8 million, up 20% from the prior-year period, as U.S. growth in its Barostim heart failure business helped the company exceed the high end of its guidance range, executives said on the company's earnings call.
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.53 per share a year ago.
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for CVRx (CVRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.43 per share a year ago.
CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.57 per share a year ago.
CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:09 PM ET CVRx, Inc. (NASDAQ:CVRX ) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Jared Oasheim - Chief Financial Officer Kevin Hykes - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division John Edward Young - Canaccord Genuity Corp., Research Division Rohin Kirit Patel - JPMorgan Chase & Co, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Michael Vallie - Unidentified Company Operator Good afternoon, ladies and gentlemen.
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.65 per share a year ago.
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
